New England Centenarian Study
Welcome to the largest and most comprehensive study of centenarians and their families in the world!
To Discover the Secrets of A Long Healthy and Happy Life…
Our two major studies are the New England Centenarian Study (founded 1995) and the multi-center Long Life Family Study (Boston Medical Center is one of 5 study sites), established in 2006.
We are actively seeking participants to be in the New England Centenarian Study. The criteria are simply subjects age 103+ years old or 100+ years with siblings.
If you would like to contact the study, please call us at 888-333-6327 (toll free) where you will hear a menu to be connected to a member of the research staff (please choose this option). You can also email the study manager, Reena Karki, MPH at firstname.lastname@example.org or the Principal Investigator, Thomas Perls MD, MPH at email@example.com.
A Summary Of Our Key Findings:
- Exceptional longevity runs strongly in families;
- Among centenarians, disability is typically compressed towards at least their early- to mid-nineties;
- With even older ages of survival, e.g., age 105+ years, morbidity is also compressed towards the end of these exceptionally long lives;
- The genetic influence upon survival increases with older and older ages of survival beyond the nonagenarian years;
- This genetic influence probably involves many genetic variants with individually modest effects, but as a group, they have a strong effect;
- But for some rare exceptions, centenarians have just as many disease-associated genetic variants as the average population. Thus, their genetic advantage is likely due to variants that slow aging and decrease risk for aging-related diseases such as heart disease, stroke, cancer, diabetes and Alzheimer’s Disease.
The New England Centenarian Study is funded by:
The William M. Wood Foundation
The Martin and Paulette Samowitz Family Foundation
Since 2006, the Long Life Family Study has been conducting a prospective study of 5,000 subjects belonging to about 550 families that demonstrate particularly impressive clustering for exceptional longevity. The Long Life Family Study is funded by and collaborates closely with The National Institute on Aging.
Our New England Centenarian Study and Long Life Family Study Staff
Please call Dr. Thomas Perls toll-free at 888-333-6327 or email him at firstname.lastname@example.org if you or a family member wish to discuss our studies, find out more information regarding enrollment or to discuss supporting our studies.
For media inquiries for the New England Centenarian Study or the Long Life Family Study, please contact:
Associate Director, Media Relations
Boston University School of Medicine
Our Recent Discoveries & Publications (of >140 peer reviewed papers)
Genes play a critical and complex role in facilitating exceptional longevity. The genetic influence becomes greater and greater with older and older ages, especially beyond 103 years of age.
- Because many genes are involved, one needs to include many different genes at once (rather than one at a time) in what is called a genetic profile to accurately categorize who is a centenarian and who is not, based on genetic data alone.
- We found 281 genetic markers that are 61% accurate in predicting who is 100 years old, 73% accurate in predicting who is 102 years old or older and 85% accurate in predicting who is 105 years old or older. In other words the prediction gets better with older and older ages beyond 100 which goes along with our hypothesis that the genetic component of exceptional longevity gets greater and greater with older and older age.
- These 281 markers point to at least 130 genes, many of which have been shown to play roles in Alzheimer’s, diabetes, heart disease, cancers, high blood pressure, and basic biological mechanisms of aging.
- Centenarians have just as many genetic variants (but for a few rare exceptions) associated with increased risk for age-related diseases (like Alzheimer’s, heart disease, stroke, diabetes and cancer) as people in the general population. Therefore, their tremendous survival advantage may in great part be due to the existence of longevity associated genetic variants that are protective and counter the negative effects of such disease gene variants.
- Participants in our study have genetic profiles that can be constructed from these 281 genetic markers (each of which has 3 variations) and these in turn are associated with specific probabilities of achieving very old age. Very interestingly, sub-groups of subjects have genetic profiles in common (what we call genetic signatures). Ninety percent of the 801 centenarians in the New England Centenarian Study can be characterized by one of 27 genetic signatures.
- These genetic signatures are also associated with different predispositions to subgroups of centenarians such as those that completely escape heart disease, or those that delay Alzheimer’s disease until the last 5% of their very long lives. This method of generating signatures will be very useful for better understanding the underlying genetics of protection from age-related diseases, modulators of rates of aging and for the field of predictive and precision medicine.
Citation: Genetic Signatures of Exceptional Longevity in Humans. Paola Sebastiani, Nadia Solovieff, Andrew T. DeWan, Kyle M. Walsh, Annibale Puca, Stephen W. Hartley, Efthymia Melista, Stacy Andersen, Daniel A. Dworkis, Jemma B. Wilk, Richard H. Myers, Martin H. Steinberg, Monty Montano, Clinton T. Baldwin, Josephine Hoh, Thomas T. Perls. PloS ONE 2012. DOI: 10.1371/journal.pone.0029848.
Many of the above genetic findings were replicated in a combination of 5 collaborating centenarian studies.
Meta-analysis of genetic variants associated with human exceptional longevity. Paola Sebastiani, Harold Bae1, Fangui X. Sun, Stacy L. Andersen, E. Warwick Daw, Alberto Malovini, Toshio Kojima, Nobuyoshi Hirose, Nicole Schupf, Annibale Puca, Thomas T Perls. Aging (Albany NY) 2013 September; 5(9): 653–661. Published online 2013 August 24. PMCID: PMC3808698
Increasing sibling relative risk of survival to older and older ages and the importance of precise definitions of “aging”, “life span” and “longevity”. Sebastiani P, Sun F, Andersen S, Black M, Perls T. J Gerontology Biol Sci. 2015;71:340-346.
Stevenson M, Bae H, Schupf N, Andersen S, Zhang Q, Perls T, Sebastiani P. Burden of disease variants in participants of the long life family study. Aging (Albany NY). 2015 Feb 5. http://www.impactaging.com/papers/v7/n2/pdf/100724.pdf
Limitations and risks of meta-analyses of longevity studies. Sebastiani P, Bae H, Gurinovich A, Soerensen M, Puca A, Perls TT. Mech Ageing Develop. 2017 Epub ahead of print: http://www.sciencedirect.com/science/article/pii/S0047637416301774
Four Genome-Wide Association Studies Identify New Extreme Longevity Variants. Sebastiani P, Gurinovich A, Bae H, Andersen S, Malovini A, Atzmon G, Villa F, Kraja AT, Ben-Avraham D, Barzilai N, Puca A, Perls TT. J Gerontol A Biol Sci Med Sci. 2017 Mar 15. doi: 10.1093/gerona/glx027.
The Older You Get, The Healthier You’ve Been
In another paper published January, 2012, we have produced perhaps some of our most exciting findings to date. Early on inThe New England Centenarian Study, we thought that centenarians had to markedly delay or even escape age-related diseases like heart attacks, stroke, diabetes and Alzheimer’s, or else they would never be able to get to their very old ages. In fact, in 1980, a Stanford researcher named James Fries proposed the “Compression of Morbidity” hypothesis which states that as one approaches the limit of human life span, they must compress the time that they develop diseases towards the very end of their life and he proposed that people around the age of 100 do this. However, in 2003 we found that many of our centenarian subjects had age related diseases even before the age of 80 (about 43%, and whom we called “survivors”), after the age of 80 (about 42% and whom we called “delayers”) and lastly, those who had no mortality-associated diseases at age 100 (about 15% and whom we called escapers). The key though was that 90% of all of the centenarians were still independently functioning at the average age of 93 years. Somehow, despite the presence of diseases, people who become centenarians don’t die from those diseases, but rather they are able to deal with them much better than other people and remain independently functioning more than 30 years beyond the age of 60. Therefore it seemed to us that for these study participants, it was not so much the compression of morbidity that was important to their survival, but rather a compression of disability.
In this current paper though, titled Health span approximates life span among many supercentenarians: Compression of morbidity at the approximate limit of life span, we have found that we just weren’t looking at old enough subjects when investigating Jim Fries’ hypothesis. As some of you know, over the past few years we have been working hard on recruiting and enrolling the most extreme old, supercentenarians who are people that live to 110 years and older. Once we enrolled our hundredth super-centenarian (by far the largest collection of supers in the world), we were able to investigate whether or not people who truly approach the limit of human lifespan actually compress their morbidity towards the end of their lives. In our study of a reference group, nonagenarians (subjects in their nineties), centenarians (ages 100-104), semi-supercentenarians (ages 105-109) and supercentenarians(ages 110+), the subjects had progressively shorter periods of their lives spent with age-related diseases, from 17.9% of their lives in the referent group, to 9.4% in the nonagenarians and down to 5.2% in the supercentenarians. These findings support the compression of morbidity hypothesis and the idea that there truly is a limit to human life span 125 years. Also the supercentenarians were much more alike in terms of the markedly delayed age of onset of age-related diseases compared to the subjects age 100-104 who were quite heterogeneous. That homogeneity indicates they must have some factors (presumably genetic) in common that allow them to be so similar. We believe that our oldest subjects, ages 105+ years, give us the best chance and discovering these genes.
Citations: Health span approximates life span among many supercentenarians: Compression of morbidity at the approximate limit of life span Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls T. J Gerontol A Biol Sci Med Sci 2012;67A:395-405.
Families Enriched for Exceptional Longevity also have Increased Health-Span: Findings from the Long Life Family Study. Paola Sebastiani, Fangui X. Sun, Stacy L. Andersen, Joseph H. Lee, Mary K. Wojczynski, Jason L. Sanders, Anatoli Yashin, Anne B. Newman, Thomas T. Perls. Front Public Health. 2013; 1: 38. PMCID: PMC3859985.
The New England Centenarian Study, along with collaborators at the Scripps Institute and the University of Florida, Gainesville, performed and published the first-ever whole genome sequence of a supercentenarian –and actually not one super, but two, both over the age of 114 years and one was a man and the other a woman. As with our paper on the genetic signatures of exceptional longevity, we found here as well that centenarians have just as many genetic variants associated with diseases as the general population. However, they likely also have longevity-associated variants that counteract such disease genes, thus allowing for slower aging and increased resistance to age-related diseases.
In this paper we also found several genes that occurred in our published genetic prediction model which had coding regions that led to differences in gene function. These findings support the validity of the genetic prediction model. The New England Centenarian Study has posted the whole genome sequences of these two subjects on a data repository (called dbGaP) based at the National Institutes of Health. This will allow researchers from around the world to access all of the data and use them for their own research. Our hope is that these data will lead to important discoveries about genes that help delay or allow the escape from age related diseases like Alzheimer’s disease.
Citation: Whole genome sequences of male and female supercentenairnas, Both ages >114 years. Sebastiani P, Riva A, Montano M, Pham P, Torkamani A, Scherba E, Benson G, Milton JN, Baldwin CT, Andersen S, Schork NJ, Steinberg MH, Perls T. Frontiers in Genetics of Aging 2012;2.
Middle Age Mothers Live Longer
There is a growing body of evidence for a substantial genetic influence upon survival to the most extreme ages. An important question is what would be the selection pressure(s) for the evolution of longevity associated genetic variants. The pressure to have a longer period of time during which women can bear children and therefore have more of them and therefore have greater success in passing one’s genes down to subsequent generations could be one such pressure. This hypothesis is consistent with the disposable soma theory where the trade-off in energy allocation between reproductive fitness and repair/maintenance functions can be delayed when longevity associated variants facilitate slower aging and the delay or prevention of age-related diseases that also adversely affect fertility. Several studies have noted an association between older maternal age and an increased odds of exceptional survival. The New England Centenarian Study assessed maternal age history in its sample of female centenarians and a birth-cohort-matched referent sample of women who survived to the cohort’s average life expectancy. Women who gave birth to a child after the age of 40 (fertility assistance was not technologically available to this cohort) had a four times greater odds of being a centenarian. Numerous investigators are now searching for and investigating genes that influence reproductive fitness in terms of their ability to also influence rate of aging and susceptibility to age-related diseases.
Citations: Middle-aged mothers live longer. Perls TT, Alpert L, Fretts RC. Nature. 1997 Sep 11;389(6647):133.PMID: 9296486
Extended maternal age at birth of last child and women’s longevity in the Long Life Family Study. Sun F, Sebastiani P, Schupf N, Bae H, Andersen SL, McIntosh A, Abel H, Elo IT, Perls TT. Menopause. 2015 Jan;22(1):26-31.
OUR PEER REVIEWED ARTICLES CONCERNING USE OF GROWTH HORMONE, TESTOSTERONE, ANABOLIC STEROIDS, DHEA, PROCAINE AND ANTI-AGING QUACKERY
The reappearance of procaine hydrochloride (Gerovital H3) for antiaging. Perls T. J Am Geriatr Soc. 2013 Jun;61(6):1024-5. doi: 10.1111/jgs.12278. No abstract available. PMID: 23772727. [PubMed – indexed for MEDLINE]
Growth hormone and anabolic steroids: athletes are the tip of the iceberg. Perls TT. Drug Test Anal. 2009 Sep;1(9-10):419-25. doi: 10.1002/dta.87. PMID: 20355224 [PubMed – indexed for MEDLINE]. Abstract: Professional Athletes’ misuse of anabolic steroids, growth hormone and other drugs are the tip of a very large, mostly ignored iceberg, made up of people who receive these drugs for such non-medical uses as body-building, school sports and “anti-aging”. Although these drugs are often used in combination, this article focuses on growth hormone. Fuelling the demand for these drugs are drug manufacturers, pharmacies, websites, clinics and their doctors.
New developments in the illegal provision of growth hormone for “anti-aging” and bodybuilding. Olshansky SJ, Perls TT. JAMA. 2008 Jun 18;299(23):2792-4. doi: 10.1001/jama.299.23.2792. No abstract available. PMID: 18560007 [PubMed – indexed for MEDLINE]
DHEA and testosterone in the elderly. Perls TT. N Engl J Med. 2007 Feb 8;356(6):636; author reply 637. No abstract available. PMID: 17288051 [PubMed – indexed for MEDLINE]
Hope drives antiaging hype. Perls TT. Cleve Clin J Med. 2006 Dec;73(12):1039-40, 1044. Review. No abstract available. PMID: 17190307 [PubMed – indexed for MEDLINE]
Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. Perls TT, Reisman NR, Olshansky SJ. JAMA. 2005 Oct 26;294(16):2086-90. No abstract available. PMID: 16249424 [PubMed – indexed for MEDLINE]
Anti-aging quackery: human growth hormone and tricks of the trade–more dangerous than ever. Perls TT. J Gerontol A Biol Sci Med Sci. 2004 Jul;59(7):682-91. PMID: 15304532 [PubMed – indexed for MEDLINE]
The hype and the reality–part I. Olshansky SJ, Hayflick L, Perls TT. J Gerontol A Biol Sci Med Sci. 2004 Jun;59(6):B513-4. No abstract available. PMID: 15215255 [PubMed – indexed for MEDLINE]
Antiaging medicine: what should we tell our patients? Perls T. Aging Health April 2010, Vol. 6, No. 2, Pages 149-154 , DOI 10.2217/ahe.10.11 (doi:10.2217/ahe.10.11)
See Also: www.hghwatch.com
To speak to someone about our research, please call our toll free number: 1-888-333-NECS (6327). Choose the option to speak with a member of our staff and you will be directed to the right person.